Cancer vaccine play Nouscom raises EUR 12M

Nouscom AG (Basel, Switzerland) raised EUR 12 million ($13.6 million) in a series A round co-led by LSP and Versant Ventures. Nouscom is developing Endovax, an antigenless vaccine based on oncolytic viruses; and Exovax, a patient-specific vaccine based on viral vectors that encode strings of cancer neoantigens. ...